CD226 and type 1 diabetes mellitus: Interestingly, Zhong et al. delineated the immune cell landscape across patients in different T1D stages by scRNA-seq, and two immune cell subsets TIGIT+CCR7− Tregs and CD226+CD8+ T cells could serve as biomarkers for monitoring T1D progression and targets for T1D treatment [75].